The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Join the Hive!

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Execution of juvenile offender in Iran ‘deeply distressing’ – UN rights chief

Crucial medical supplies airlifted to north-east Syria to meet ‘desperate need’

Who and why want the EU-US trade agreement here and now

‘Compelling case’ for urgency around global disarmament, UN-led forum told

E-cigars: Improbable ally or enemy in disguise?

“A Junior Enterprise is run only by students.. there are no professors or managers that can help you solve your problems”

Intervene, don’t overthink – the new mantra of systems design

TTIP’s 11th round major takeaways and the usual “leaked” document

Opposite cultures: Should it be a problem?

Pledging ongoing UN support during visit to cyclone-hit areas, Guterres praises resilience of Mozambicans

Air quality: Commission takes action to protect citizens from air pollution

Sustainable development demands a broader vision, says new OECD Development Centre report

How oysters are cleaning New York’s polluted harbor

EU seeks foreign support on 5G from Mobile World Congress 2015 as the “digital gold rush” begins

SMEs and micro firms sinking together with south Eurozone

“The markets have moved on renewables, policy makers must keep up”, A Sting Exclusive by Erik Solheim, Head of UN Environment

UN Human Rights Council stands firm on LGBTI violence, Syria detainees and Philippines ‘war on drugs’

UK’s PM Theresa May asks for a two-year Brexit transition plan as negotiations round kicks off

Drought in Europe: Member States agree on support measures proposed by the Commission

Thursday’s Daily Brief: Climate crisis and food risks, fresh violence threat for millions of Syrians, calls for calm in Kashmir

Trade in counterfeit goods costs UK economy billions of euros

Refugee crisis update: EU still lacks solidarity as Hungary and Slovakia refuse to accept EU Court’s decision

How to future-proof India’s economy

EU’s judicial cooperation arm, Eurojust, to become more effective with new rules

Our healthcare systems are ailing. Here’s how to make them better

How universities can become a platform for social change

UNICEF backpacks used as a haunting symbol to call for greater protection of children living in conflict

Radioactive nuclear waste is a global threat. These scientists may have a new solution

OECD leading multilateral efforts to address tax challenges from digitalisation of the economy

Iraq protests: UN calls for national talks to break ‘vicious cycle’ of violence

A Europe that protects: EU reports on progress in fighting disinformation ahead of European Council

Commission presents EU-Vietnam trade and investment agreements for signature and conclusion

Blue bonds: What they are, and how they can help the oceans

Obesity rates soar due to dramatic global diet shift, says UN food agency

Coronavirus crisis: “Commission will use all the tools at its disposal to make sure the European economy weathers the storm”

Mexico must increase foreign bribery enforcement: full implementation of anti-corruption reforms could help

Two peacekeepers killed in an attack against UN convoy in Mali

EuroLat plenary in Panama: control of trade talks and fight against crime

Is the English language too powerful?

Trade: First year of the EU-Japan Economic Partnership Agreement shows growth in EU exports

UN agriculture agency digs in to help forests and farms build resilience to climate change

Disaster Medicine in Medical Education: the investment you just can´t afford to ignore

A Sting Exclusive: “Infrastructure can lay the groundwork for the Sustainable Development Goals” by Mr Fulai Sheng, UN Environment Senior Economist

Commission proposes a governance framework for the Budgetary Instrument for Convergence and Competitiveness

Why enterprise risk management is the future for banks

Streaming music isn’t as green as you might think. Here’s why

‘Young people care about peace’: UN Youth Envoy delivers key message to Security Council

Why the ECB prepares to flood the markets with more and free of charge euro; everybody needs that now

Deal on tightening the rules to stop terrorists from using homemade explosives

A Europe that protects: Continued efforts needed on security priorities

International community renews commitment to multilateral efforts to address tax challenges from digitalisation of the economy

EU invests more than €100 million in new LIFE Programme projects to promote a green and climate-neutral Europe

What the car industry has done to help fight climate change – and what it needs to do next

MWC 2016 LIVE: Freemium MVNO model a success, claims FreedomPop head

This company is breeding millions of insects in the heart of London

Millions more migrant workers, means countries lose ‘most productive part’ of workforce

‘Brutal weather’ continues as Rohingya refugee children endure devastating rainfall in Bangladesh

Turkey remains numb while its economy is expected to shrink further due to a cocktail of EU and US sanctions

More taxpayers’ money for the banks

Electronic cigarettes – The alternative we’ve been looking for?

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s